Nuala Moran

Can European R&D play its way to the top of the international league? In an unprecedented gathering Science|Business brought together some of the leading protagonists to discuss possible tactics.

How should the EU respond to the movement in innovation-based research to the East? The UK think tank Demos has some suggestions.

IPOs are up in the year to date. But the value of these deals is down. Rather than cashing out, VCs are getting a ticket to stay on for a white-knuckle ride.

The technology funding gap has long been with us, but in drug discovery it has widened into a chasm.

Soon it won’t be possible to fund the huge enterprises of the leading pharma companies with a handful of blockbuster drugs. The only question is whether they can change and innovate in time.

The days of medical charities passively handing out grants and waiting to hear of any results are over. Now the money comes attached to sophisticated, target-driven deals.

Two major Polish institutions, the universities of Warsaw and Wroclaw have joined forces to form PLERCIM, and the new body has become a member of ERCIM, the European Research Consortium for Informatics and Mathematics.

An historic all-Ireland collaborative research partnership uniting universities in Northern Ireland and the Republic has been struck between Queen’s University Belfast (QUB), Trinity College Dublin (TCD) and University College Dublin (UCD).

Ernst & Young’s 21st annual analysis of the standing of the biotechnology industry shows grounds for cautious optimism as European biotech perked up after a miserable four years of restructuring.

If the European Union favours innovation, as it claims, can we have some action on advanced therapies to prove it, please?